Navigation Links
Niusule Announces Key Additions to Management Team
Date:11/13/2009

MONROVIA, Calif. and HANGZHOU, China, Nov. 13 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that Mr. Ping (Vince) Huang was named the Company's chief financial officer on November 6, 2009. Previously, Ms. Qinghua Hu, the Company's chief executive officer, also served as Niusule's CFO. The Company also retained Mr. Pei Pei as chief marketing officer of Niusule Bioengineering (Hangzhou) Co. Ltd. (Niusule Bioengineering), the Company's subsidiary in China.

Mr. Huang's work experience includes key positions in investment banking, consulting, and business development. He most recently served as an investment consultant for PIEPS, an affiliate of Gemstong Capital, where he initiated and managed qualitative and quantitative analysis for buyout execution. Mr. Huang also worked on the University of Alabama-Birmingham's life-science entrepreneurship program, where he was responsible for analysis and market research related to the commercialization of intellectual property. Prior to that, Mr. Huang was a business analyst for Beijing Kawin Biotech Co., Ltd., coordinating regulatory approvals for manufacturing and control processes. He holds a Bachelor of Engineering degree with a major in Biopharmaceuticals from China Pharmaceutical University and a Masters of Business Administration specializing in Finance from the UCLA Anderson School of Management. Mr. Huang has a Ph.D. in Pharmacology and Toxicology from the University of Alabama, Birmingham. He is fluent in English and Mandarin.

Mr. Pei has a strong marketing background in the Pharmaceutical and Bioengineering industry. Prior to joining Niusule, he served as Marketing Manager of Zhejiang at Shanghai Longbin Biotechnology Co., Ltd. He also worked as Manager of Zhejiang Branch, at Beijing Sinceretime Pharmaceutical Company and as Sales Director of Shanghai Asia Pioneer Pharmaceutical Co.,

Ltd. Mr. Pei has a college degree from China University of Geosciences.

"We would like to welcome Mr. Huang and Mr. Pei on board. We look forward to working with them and believe they will make meaningful contributions to Niusule. Mr. Huang's solid financial background will enhance our corporate finance, financial reporting and internal controls. I am also pleased that Mr. Pei with his extensive marketing experience will be leading our aggressive market expansion strategy and assisting Niusule to achieve its goals," commented Ms. Qinghua Hu, CEO of Niusule Biotech Corp. "I am delighted that with these additions, I can now focus my full attention on business strategy and planning our future growth and development," added Ms. Hu.

About Niusule Biotech Corp.

Niusule Biotech Corp. ("Niusule" or "the Company"), through its wholly owned subsidiary Niusule Bioengineering (Hangzhou) Co. Ltd., markets and distributes health food and related products manufactured in the US to Chinese consumers. The Company launched its Niusule Gummy Bears nutritional supplements for children in September 2009 and its PlantFusion protein powder in July 2009. Niusule currently has a retail distribution network comprised of 36 outlets at high-end supermarkets and shopping malls in Zhejiang province and is aggressively seeking to expand into other regions in China. Niusule was founded in April 2008 and is headquartered in Monrovia, California. For more information, contact CCG Investor Relations directly or go to Niusule's website at http://www.niusule.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. You are urged to consider these factors care in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

    Contact:

    Jeff Tsang
    Niusule Biotech Corp.
    (626) 446-4688
    Email: ir@niusule.com
    Website: www.niusule.com

    Mabel Zhang
    CCG Investor Relations
    (310) 954-1353
    mabel.zhang@ccgir.com
    www.ccgirasia.com

SOURCE Niusule Biotech Corp.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Announces Secondary Equity Offering
2. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
3. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
4. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
5. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
6. Milestone Scientific Announces Third Quarter 2009 Results
7. EF Johnson Technologies Announces Third Quarter Results
8. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
9. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
10. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
11. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):